Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eRADicAte: Radium Ra 223 Dichloride + Abiraterone Acetate + Prednisone in Prostate Cancer
NCT02097303Phase 2Completed
- Sponsor
- Carolina Research Professionals
- Start
- Mar 2014
- Primary completion
- Dec 2015
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Carolina Research Professionals. Primary endpoints: Quality-of-Life Clinically Meaningful Improvement at 32 weeks and Pain Clinically Meaningful Improvement at 32 weeks. Started Mar 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02097303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097303.